Get started
Author

Toshiharu Komori

Observed names: TOSHIHARU KOMORI, 小森, 敏治
OpenAlex ID: A5030733486
Ash1l Methylates Lys36 of Histone H3 Independently of Transcriptional Elongation to Counteract Polycomb Silencing
2013 · Hitomi Miyazaki, Ken Higashimoto, et al. · PLoS Genetics · 89
PDF
TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
2019 · Hibiki Udagawa, Shinichi Hasako, et al. · Molecular Cancer Research · 76
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use
2023 · Satoru Ito, Sachie Otsuki, et al. · ACS Medicinal Chemistry Letters · 50
PDF
Role of human transcription elongation factor DSIF in the suppression of senescence and apoptosis
2009 · Toshiharu Komori, Naoto Inukai, et al. · Genes to Cells · 26
Schlafen11 Expression Is Associated With the Antitumor Activity of Trabectedin in Human Sarcoma Cell Lines
2019 · JUNYA IWASAKI, TOSHIHARU KOMORI, et al. · Anticancer Research · 22
Cellular dynamics of the negative transcription elongation factor NELF
2009 · Tetsu M.C. Yung, Takashi Narita, et al. · Experimental Cell Research · 13
Abstract 659: Synergistic antitumor activity of futibatinib (TAS-120), a FGFR1-4 inhibitor, and PI3K pathway inhibitors
2020 · Akihiro Miura, Hiroshi Sootome, et al. · Cancer Research · 2
Abstract 661: Synergistic antitumor activity of futibatinib, an FGFR1-4 inhibitor, and TAS-117, a selective AKT inhibitor, in FGFR-deregulated cancer models
2020 · Junya Iwasaki, Takuya Kuramoto, et al. · Cancer Research · 2
Abstract 564: Futibatinib (TAS-120) plus chemotherapy demonstrates a synergistic effect across various FGFR-deregulated cancer cell lines and xenograft models
2020 · Hiroshi Sootome, Akihiro Miura, et al. · Cancer Research · 2
Discovery of Novel Oral Covalent Inhibitors Targeting Active GTP-Bound KRASG12C with Potent Antitumor Activity
2026 · Juan del Pozo, Elisabeth Hennessy, et al. · Journal of Medicinal Chemistry
Tables S1-3 and Figures S1-4 from TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
2023 · Hibiki Udagawa, Shinichi Hasako, et al.
PDF
Tables S1-3 and Figures S1-4 from TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
2023 · Hibiki Udagawa, Shinichi Hasako, et al.
Data from TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
2023 · Hibiki Udagawa, Shinichi Hasako, et al.
Abstract 1329: Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor
2019 · Hibiki Udagawa, Shinichi Hasako, et al. · Experimental and Molecular Therapeutics
Abstract 1329: Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor
2019 · Hibiki Udagawa, Shinichi Hasako, et al. · Cancer Research
Works count: 16
Citation count: 282
H-index: 6
I10-index: 6
Year
Topic
Type